Windtree Announces Istaroxime Phase 2 Interim Analysis in SCAI Stage C Cardiogenic Shock Patients

Core Insights - Windtree Therapeutics is advancing istaroxime, a dual-mechanism therapy for cardiogenic shock, following positive interim analysis results from the SEISMiC C Phase 2 study [1][4][5] - The study demonstrated that istaroxime maintains a safety profile consistent with previous trials, showing no new safety signals and physiological improvements [1][3] Group 1: Study Overview - The SEISMiC C Study is a global, placebo-controlled, double-blinded trial assessing istaroxime in patients with severe cardiogenic shock (SCAI Stage C) [2] - Istaroxime was added to standard care, including inotropes and vasopressors, and showed potential advantages in efficacy and safety compared to existing therapies [2][4] - The interim analysis included the first 20 patients, revealing no new safety concerns or excess arrhythmias [3] Group 2: Istaroxime Profile - Istaroxime is a first-in-class therapy designed to enhance both systolic and diastolic cardiac function, improving myocardial contractility and facilitating relaxation [5] - Previous Phase 2 studies indicated that istaroxime significantly improves cardiac function and blood pressure without increasing heart rate or causing significant rhythm disturbances [5] Group 3: Company Background - Windtree Therapeutics operates with multiple divisions, including a cryptocurrency treasury strategy and therapeutic pipelines, actively seeking long-term development partners [6]